110 completed, 22 recruiting, 13 active not recruiting, 13 terminated. 64 Phase 3, 40 Phase 2, 22 Phase 1, 19 Phase 4, 5 Not applicable.
Follow Ustekinumab: new trials by email Literature Review of Ustekinumab trials Research Report on Ustekinumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Utilization of a Microdevice for Psoriasis and Atopic Dermatitis In situ cutaneous microdevice, Triamcinolone, 5-Fluorouracil - Psoriasis, Atopic Dermatitis | Phase 4 | Not yet recruiting | University of California, San Francisco | 10 | 2026-08-01 | 2026-06-03 |
| Digestive Evolution of Children With Crohn's Disease or Ulcerative Colitis Whose Anti-TNFα Treatment Was Switched to Ustekinumab Due to Paradoxical Psoriasis, switch of anti TNF for ustekinumab for paradoxical psoriasis. - Chronic Inflammatory Bowel Diseases | Not applicable | Recruiting | Centre Hospitalier Universitaire de Nice | 40 | 2026-04-20 | 2026-06-25 |
| Biologics in Folliculitis Decalvans : an Adaptative Trial Research Adalimumab, Ustekinumab, Baricitinib - Folliculitis Decalvans (FD) | Phase 2 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 120 | 2026-04-01 | 2025-12-05 |
| Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Population Non-Interventional Study - Ulcerative Colitis | Active not recruiting | Pfizer | 4000 | 2026-04-01 | 2026-10-15 | |
| Efficacy of Different Biological Treatments in Patients With Inflammatory Bowel Disease After One Year of Treatment in Upper Egypt adalimumab, infliximab, ustekinumab, golimumab, and vedolizumab - Inflamatory Bowel Disease (Crohn's and Ulcerative Colitis) | Not yet recruiting | Assiut University | 95 | 2026-03-01 | 2026-03-27 | |
| Guselkumab Vs Ustekinumab in Stricturing Crohn's Disease Guselkumab (GUS), Ustekinumab (UST) - CD - Crohn's Disease, Stricture; Bowel | Recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 100 | 2026-03-01 | 2026-03-02 | |
| Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients Ustekinumab - Cancer | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 10 | 2026-02-24 | 2026-09-14 |
| Comparison of the Efficacy of Different Biologic Agents in Preventing Postoperative Endoscopic Recurrence of Crohn's Disease Infliximab, Adalimumab, Vedolizumab - Inflamatory Bowel Disease, Crohn Disease (CD) | Recruiting | Shanghai 10th People's Hospital | 198 | 2026-01-16 | 2026-07-10 | |
| Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty Methotrexate, Sulfasalazine, Hydroxychloroquine - Rheumatic Disease | Phase 2 | Recruiting | NYU Langone Health | 80 | 2025-12-12 | 2026-07-09 |
| Risankizumab for Fibrostenotic Crohn's Disease Treatment Ustekinumab, Risankizumab - Crohn Disease, Crohn Disease and Ulcerative Colitis | Phase 3 | Not yet recruiting | First Affiliated Hospital of Wenzhou Medical University | 260 | 2025-10-20 | 2025-09-16 |
| De-escalation of Ustekinumab Therapy in Patients With Crohn's Disease and Ulcerative Colitis Ustekinumab 90 mg SC q8w, Ustekinumab 90 mg SC q12w - Crohn Disease (CD), Ulcerative Colitis (UC) | Phase 4 | Recruiting | McGill University Health Centre/Research Institute of the McGill University Health Centre | 115 | 2025-10-08 | 2025-12-26 |
| Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK) Deucravacitinib, Ustekinumab - Plaque Psoriasis | Phase 3 | Recruiting | Bristol-Myers Squibb | 3040 | 2025-09-22 | 2026-10-13 |
| Ustekinumab and Upadacitinib for Induction and Maintenance Therapy in Patients With Refractory Crohn's Disease: A Multicenter, Randomized, Parallel-Controlled Study Ustekinumab (approximately 6 mg/kg), Upadacitinib - Crohn's Disease Aggravated, Crohn's Disease in Remission | Phase 3 | Not yet recruiting | Sixth Affiliated Hospital, Sun Yat-sen University | 454 | 2025-09-10 | 2025-09-02 |
| MOdel-Informed Precision Dosing of Ustekinumab and VEdolizumab in Inflammatory Bowel Disease PK-model to decide when to dose Vedolizumab and Ustekinumab - Inflammatory Bowel Diseases, Crohn Disease | Phase 4 | Not yet recruiting | Odense University Hospital | 166 | 2025-09-01 | 2025-07-31 |
| A Direct Head-to-head Comparison of Ustekinumab With Infliximab for the Treatment of Ulcerative Colitis Ustekinumab 90 mg, Infliximab - Ulcerative Colitis (UC) | Active not recruiting | Helwan University | 100 | 2025-05-15 | 2026-09-17 | |
| A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis JNJ-77242113, Matching Placebo to JNJ-77242113, Ustekinumab - Plaque Psoriasis | Phase 3 | Active not recruiting | Janssen Research & Development, LLC | 752 | 2025-04-15 | 2026-09-25 |
| ROLL'YN-UST: an Observational Study in Patients Treated by Steqeyma®, an Ustekinumab Biosimilar Ustekinumab 45 mg, Ustekinumab 90 mg - Crohn Disease, Plaque Psoriasis | Recruiting | Celltrion HealthCare France | 225 | 2025-03-17 | 2025-05-30 | |
| Comparison of Ustekinumab, Infliximab and Combination Therapy in Moderately to Severely Active Ulcerative Colitis Infliximab, Ustekinumab - Ulcerative Colitis, Inflammatory Bowel Diseases | Phase 2 | Recruiting | Medical University of Lodz | 172 | 2025-02-17 | 2025-05-15 |
| Quantitative Fluorescence Molecular Imaging of Ustekinumab-800CW to Elucidate the Drug Distribution Throughout Inflamed Tissue in Crohn's Disease and Psoriasis. Ustekinumab - Psoriasis, Crohn Disease | Phase 1 | Recruiting | University Medical Center Groningen | 56 | 2025-01-06 | 2025-01-15 |
| Testing the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease Fluconazole, Placebo, IL-23 Therapy - Crohn's Disease, Inflammatory Bowel Diseases | Phase 3 | Recruiting | Weill Medical College of Cornell University | 120 | 2024-10-04 | 2026-08-20 |
Showing 20 of 182. Sign in to see all of them.
Crohn Disease (53) · Psoriasis (49) · Colitis, Ulcerative (19) · Arthritis, Psoriatic (16) · Inflammatory Bowel Diseases (10) · Skin Diseases (5) · Arthritis, Rheumatoid (4) · Dermatitis, Atopic (4) · Lupus Erythematosus, Systemic (4) · Spondylitis, Ankylosing (4) · Arthritis, Juvenile (3) · Diabetes Mellitus, Type 1 (3) · Autoimmune Diseases (2) · Axial Spondyloarthritis (2) · Constriction, Pathologic (2)
Janssen Research & Development, LLC (30) · Centocor, Inc. (10) · Janssen Pharmaceutical K.K. (5) · AbbVie (4) · National Institute of Allergy and Infectious Diseases (NIAID) (4) · Bristol-Myers Squibb (3) · Janssen-Cilag Ltd. (3) · Novartis Pharmaceuticals (3) · Second Affiliated Hospital, Zhejiang University, School of Medicine (3) · Universitaire Ziekenhuizen KU Leuven (3) · AO GENERIUM (2) · Alvotech Swiss AG (2) · Amgen (2) · Assistance Publique - Hôpitaux de Paris (2) · Bausch Health Americas, Inc. (2)
United States (80) · Germany (44) · Canada (41) · Poland (40) · Belgium (33) · France (33) · Hungary (32) · United Kingdom (31) · Spain (28) · Russia (24) · China (22) · South Korea (21) · Australia (19) · Italy (19) · Netherlands (18)
Hatice N Sen, M.D. (2) · Ivan J Fuss, M.D. (2) · Jan Dutz, MD FRCPC (2)
PMID 40357993, PMID 30739254, PMID 31054118, PMID 31667790, PMID 33687069, PMID 26422722, PMID 27098404, PMID 27483458, PMID 30225992, PMID 30328108, PMID 30471012, PMID 31070869, PMID 32207067, PMID 32209721, PMID 33052382, PMID 34606048, PMID 34870789, PMID 34921669, PMID 35839335, PMID 36150926, PMID 36334236, PMID 36995469, PMID 37906417, PMID 39120848, PMID 39264399, PMID 17287478, PMID 18486739, PMID 18486740, PMID 18703004, PMID 18706417, PMID 19217154, PMID 19317608, PMID 20071701, PMID 22751454, PMID 23075178, PMID 23468464, PMID 23512638, PMID 23769296, PMID 24389297, PMID 25034562, PMID 25428650, PMID 25434285, PMID 25543678, PMID 25594886, PMID 26092291, PMID 26093174, PMID 26097039, PMID 26641955, PMID 27959607, PMID 28087506
2023 (7), 2014 (5), 2016 (5), 2015 (4), 2017 (4), 2019 (4), 2005 (3), 2009 (3), 2018 (3)